<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632797</url>
  </required_header>
  <id_info>
    <org_study_id>1224/2018</org_study_id>
    <nct_id>NCT04632797</nct_id>
  </id_info>
  <brief_title>Cryotherapy vs. Cryocompression for Preventing Chemotherapy-induced-peripheral-neuropathy in Women Undergoing Chemotherapy</brief_title>
  <official_title>CROPSI Study A Randomized, Observer-blinded Clinical Trial Evaluating Effectiveness of Cryotherapy vs. Cryocompression for Preventing CIPN in Women Undergoing Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study's aim is to show a benefit of Cryocompression (cooling hands with additional&#xD;
      compression of the hands) in comparison to Cryotherapy (just cooling hands) in female cancer&#xD;
      patients (with gynecological cancer) receiving chemotherapy with taxanes.&#xD;
&#xD;
      Patients who are not eligible for either cryocompression or cryotherapy are included in a&#xD;
      control group.&#xD;
&#xD;
      The expected benefits with additional compression to the cryotherapy are reduction of&#xD;
      chemotherapy induced polyneuropathy and reduced nail changes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this randomized, observer blinded, monocentric study 196 patients will be included in a&#xD;
      four years period.&#xD;
&#xD;
      The patients will be 1 to 1 randomized in either cryocompression or cryotherapy. Patients who&#xD;
      are not eligible for either cryocompression or cryotherapy will be included in the control&#xD;
      group.&#xD;
&#xD;
      Additionally every patient (excluding the control group) receives cryotherapy for the feet.&#xD;
&#xD;
      Before receiving the first chemotherapy CTCAE, Semmes-Weinstein monofilament examination&#xD;
      (SWME), vibration test for hand and feet, and nerve conduction velocity (NCV) only for hands.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">February 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 3, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1 to 1 randomization in either cryocompression or cryotherapy of the hands</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>It is an observer blinded study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>NCV (nerve conduction velocity)</measure>
    <time_frame>4 years</time_frame>
    <description>Comparison of efficacy of cryotherapy vs. cryocompression regarding occurence of ≥ CIPN III°</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CTCAE 4.03</measure>
    <time_frame>4 years</time_frame>
    <description>Comparison of efficacy of cryotherapy vs. cryocompression regarding occurence of ≥ CIPN III°</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SWME (Semmes Weinstein monofilament examination)</measure>
    <time_frame>4 years</time_frame>
    <description>Comparison of efficacy of cryotherapy vs. cryocompression regarding occurence of ≥ CIPN III°</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tuning-fork-test</measure>
    <time_frame>4 years</time_frame>
    <description>Comparison of efficacy of cryotherapy vs. cryocompression regarding occurence of ≥ CIPN III°</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EORTC QoLCIPN20</measure>
    <time_frame>4 years</time_frame>
    <description>Patient-reported outcomes (PRO)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuro-QoL Domain for Upper Extremity (FineMotor, ADL)</measure>
    <time_frame>4 years</time_frame>
    <description>Patient-reported outcomes (PRO)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>National Cancer Institute Common Toxicity Criteria version 2</measure>
    <time_frame>4 years</time_frame>
    <description>Changes of nails</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time frame until polyneuopathy occurs</measure>
    <time_frame>4 years</time_frame>
    <description>time frame until polyneuopathy occurs whilst receiving Taxanes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Chemotherapy-induced Peripheral Neuropathy</condition>
  <condition>Chemotherapeutic Toxicity</condition>
  <condition>Chemotherapeutic Agent Toxicity</condition>
  <arm_group>
    <arm_group_label>Cryocompression</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group receive cryocompression for the hands.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group receive cryotherapy for the hands.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hilotherm Chemo Care</intervention_name>
    <description>Application of Hilotherm Chemo Care gloves for constant cryotherapy during chemotherapy application.</description>
    <arm_group_label>Cryocompression</arm_group_label>
    <arm_group_label>Cryotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with breast cancer or other gynecological tumors&#xD;
&#xD;
          -  planned neoadjuvant, adjuvant or palliative chemotherapy&#xD;
&#xD;
          -  &lt;/= two lines chemotherapy as pre-therapy (adjuvant chemotherapy counts as one line)&#xD;
&#xD;
          -  at least three cycles of chemotherapy with taxanes&#xD;
&#xD;
          -  written consent&#xD;
&#xD;
          -  18 years and older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PNP &gt;/= 2&#xD;
&#xD;
          -  neuralgia&#xD;
&#xD;
          -  metastases in bones, metastases in soft tissue (located in skin, hands or feet)&#xD;
&#xD;
          -  Raynaud syndrome&#xD;
&#xD;
          -  peripheral arterial ischemia&#xD;
&#xD;
          -  hand-feet syndrome&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Brunner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Innsbruck</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Brunner</last_name>
    <phone>+4351250481194</phone>
    <email>c.brunner@tirol-kliniken.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Cervix Cancer</keyword>
  <keyword>Endometrium Cancer</keyword>
  <keyword>Ovarial Cancer</keyword>
  <keyword>CIPN</keyword>
  <keyword>Taxane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

